Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries

NCT04914234 | Recruiting Phase 4

• 1 other identifier: DTH: 21002
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives: To compare the safety and efficacy of oral atenolol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during nasal surgeries. Background: Mucosal bleeding is the most frequent complication with nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, increases operation time, and consequently increases blood loss. There are several pharmacological and non-pharmacological techniques for the appropriate control of intraoperative bleeding. Patients and Methods: This was a prospective, randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received oral atenolol, and group M, received oral metoprolol.

Conditions

Hypotension Drug-Induced

Keywords

atenolol; controlled hypotension; metoprolol; nasal surgery

Outcome Measures

Primary Outcomes (1)

• Mean and Standard deviation of Blood loss (ml)(mean±SD)

  Amount of blood loss at the end of surgery

  5 minutes after the end of surgery

Study Arms (2)

Group A (n=30)

ACTIVE COMPARATOR

Atenolol group

Drug: Atenolol Succinate Oral Tablet

Group M (n=30)

ACTIVE COMPARATOR

Metoprolol group

Drug: Metoprolol Succinate Oral Tablet

Interventions

Atenolol Succinate Oral Tablet DRUG

Atenolol 50 mg

Also known as: Tenormin tablets

Group A (n=30)

Metoprolol Succinate Oral Tablet DRUG

Metoprolol 100 mg

Also known as: Seloken ZOC tablets

Group M (n=30)

Eligibility Criteria

• Age: 21 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• American Society of Anesthesiologists (ASA) physical status ≤ II
• Age from 21 to 50 years

You may not qualify if:

• ASA physical status \> II
• Age \< 21 years or \> 50 years
• Pregnant women
• Breastfeeding
• Bronchial asthma
• Chronic obstructive pulmonary disease
• Diabetes Mellitus
• Hypertension
• Ischemic heart disease
• Rheumatic heart disease
• Heart failure
• Heart block
• Sick sinus syndrome
• Sinus bradycardia
• Chronic hypotension

Sponsors & Collaborators

• Damanhour Teaching Hospital: lead

Study Sites (1)

Damanhour Teaching Hospital

Damanhūr, El-Beheira, Egypt

RECRUITING

MeSH Terms

Conditions

Hypotension

Interventions

Atenolol; Metoprolol

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Phenoxypropanolamines; Propanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Propanols; Amines

Study Officials

• Ahmed M Shaat, MD

  Damanhour Teaching Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ahmed M Shaat, MD

CONTACT

00201223482709; ahmedshaat99@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 31, 2021
• First Posted: June 4, 2021
• Study Start: August 1, 2025
• Primary Completion: January 15, 2026
• Study Completion: January 30, 2026
• Last Updated: August 21, 2025

Record last verified: 2025-08

Locations

EG (1)